- document
-
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PSCK9) neutralizing antibodies effectively lower plasma cholesterol levels and decrease cardiovascular events but also raised some concern that cognitive function could worsen as a side effect. Here, we performed experiments in mice to characterize the effect of anti-PCSK9 antibodies...article 2021
- document
-
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of...article 2020
- document
-
Schuster, S. (author), Rubil, S. (author), Endres, M. (author), Princen, H.M.G. (author), Boeckel, J.N. (author), Winter, K. (author), Werner, C. (author), Laufs, U. (author)LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To characterize their effect on atherogenesis, APOE*3Leiden.CETP mice were fed a high cholesterol/high fat...article 2019